These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 17346094)

  • 1. Appropriate use of NSAIDs: considering cardiovascular risk in the elderly.
    Stillman MJ; Stillman MT
    Geriatrics; 2007 Mar; 62(3):16-21. PubMed ID: 17346094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Choosing nonselective NSAIDs and selective COX-2 inhibitors in the elderly. A clinical use pathway.
    Stillman MJ; Stillman MT
    Geriatrics; 2007 Feb; 62(2):26-34. PubMed ID: 17291140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
    Scheiman JM; Hindley CE
    Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
    Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S
    Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents.
    Chan FK; Abraham NS; Scheiman JM; Laine L;
    Am J Gastroenterol; 2008 Nov; 103(11):2908-18. PubMed ID: 18853980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks.
    Rostom A; Moayyedi P; Hunt R;
    Aliment Pharmacol Ther; 2009 Mar; 29(5):481-96. PubMed ID: 19053986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs.
    Hur C; Chan AT; Tramontano AC; Gazelle GS
    Ann Pharmacother; 2006 Jun; 40(6):1052-63. PubMed ID: 16720709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
    Dajani EZ; Islam K
    J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():117-33. PubMed ID: 18812633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular issues of COX-2 inhibitors and NSAIDs.
    Wong M; Chowienczyk P; Kirkham B
    Aust Fam Physician; 2005 Nov; 34(11):945-8. PubMed ID: 16299629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference.
    Tannenbaum H; Bombardier C; Davis P; Russell AS;
    J Rheumatol; 2006 Jan; 33(1):140-57. PubMed ID: 16331802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.
    Joshi GP; Gertler R; Fricker R
    Anesth Analg; 2007 Dec; 105(6):1793-804, table of contents. PubMed ID: 18042885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E; Nedjar H
    Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular complications of non-steroidal anti-inflammatory drugs.
    Fosslien E
    Ann Clin Lab Sci; 2005; 35(4):347-85. PubMed ID: 16254252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk.
    Hermann M; Ruschitzka F
    Intern Med J; 2006 May; 36(5):308-19. PubMed ID: 16650196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs.
    van der Linden MW; van der Bij S; Welsing P; Kuipers EJ; Herings RM
    Ann Rheum Dis; 2009 May; 68(5):668-73. PubMed ID: 18495734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular adverse effects of coxibs.
    Prescrire Int; 2002 Dec; 11(62):181-2. PubMed ID: 12472094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
    Schneeweiss S; Solomon DH; Wang PS; Rassen J; Brookhart MA
    Arthritis Rheum; 2006 Nov; 54(11):3390-8. PubMed ID: 17075817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changing perceptions and practices regarding aspirin, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs among US primary care providers.
    Elnachef N; Scheiman JM; Fendrick AM; Howden CW; Chey WD
    Aliment Pharmacol Ther; 2008 Nov; 28(10):1249-58. PubMed ID: 18729848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of NSAIDs in rheumatic disorders 2005: a global perspective.
    Kean WF; Buchanan WW
    Inflammopharmacology; 2005; 13(4):343-70. PubMed ID: 16354389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular risks of cyclooxygenase inhibition.
    Stacy ZA; Dobesh PP; Trujillo TC
    Pharmacotherapy; 2006 Jul; 26(7):919-38. PubMed ID: 16803424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.